Lower central serotonergic responsivity is associated with preclinical carotid artery atherosclerosis

Stroke

Volumn 38, Issue 8, 2007, Pages 2228-2233

  Muldoon, Matthew F ^a   Mackey, Rachel H ^b   Sutton Tyrrell, Kim ^b   Flory, Janine D ^d   Pollock, Bruce G ^e   Manuck, Stephen B ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Atherosclerosis; Central nervous system; Serotonin

Indexed keywords

CITALOPRAM; PROLACTIN; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; B SCAN; CAROTID ARTERY; CONFIDENCE INTERVAL; FEMALE; GENDER; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RACE; SEROTONINERGIC SYSTEM; VASCULAR DISEASE; AUTONOMIC NEUROPATHY; BLOOD; CAROTID ARTERY OBSTRUCTION; CENTRAL NERVOUS SYSTEM; DOWN REGULATION; ECHOGRAPHY; GLUCOSE BLOOD LEVEL; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIPID METABOLISM; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; SECRETION;

ADULT; AUTONOMIC NERVOUS SYSTEM DISEASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CAROTID STENOSIS; CENTRAL NERVOUS SYSTEM; CITALOPRAM; DOWN-REGULATION; FEMALE; HUMANS; HYPERTENSION; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROLACTIN; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 34548226400     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.106.477638     Document Type: Article

References (55)

1. Sanders-Bush E, Mayer SE. 5-Hydroxytryptamine (serotonin): receptor agonists and antagonists. In: Brunton LL, Parker KL, Buxton ILO, Blumenthal DK, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: The McGraw-Hill Companies; 2006:297-315.
2. Quattrone A, Tedeschi G, Aguglia U, Scopacassa F, DiRenzo GF, Annunziato L. Prolactin secretion in man, a useful tool to evaulate the activity of drugs on central 5-hydroxytryptaminergic neurons: studies with fenfluramine. Br J Pharmacol. 1983;16:471-475.
3. Yatham LN, Steiner M. Neuroendocrine probes of serotonergic function: a critical review. Life Sciences. 1993;53:447-463.
4. Mann JJ, Mcbride PA, Malone KM, Demeo M, Keilp J. Blunted serotonergic responsivity in depressed inpatients. Neuropsychopharmacology. 1995;13:53-64.
5. Flory JD, Mann JJ, Manuck SB, Muldoon MF. Recovery from major depression is not associated with normalization of serotonergic function. Biol Psych. 1998;43:320-326.
6. Muldoon MF, Mackey RH, Williams KV, Korytkowski MT, Flory JD, Manuck SB. Low central nervous system serotonergic responsivity is associated with the metabolic syndrome and physical inactivity. J Clin Endocrinol Metab. 2004;89:266-271.
7. Muldoon MF, Sved AF, Flory JD, Perel JM, Matthews KA, Manuck SB. Inverse relationship between fenfluramine-induced prolactin release and blood pressure in humans. Hypertension. 1998;32:972-975.
8. Muldoon MF, Mackey RH, Korytkowski MT, Flory JD, Pollock BG, Manuck SB. The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. J Clin Endocrinol Metab. 2006;91:718-721.
9. Fumeron F, Betoulle D, Nicaud V, Evans A, Kee F, Ruidavets JB, Arveiler D, Luc G, Cambien F. Serotonin transporter gene polymorphism and myocardial infarction: Etude Cas-te'moins de' l'Infarctus du Myocarde (ECTIM). Circulation. 2002;105:2943-2945.
10. Coto E, Reguero JR, Alvarez V, Morales B, Batalla A, Gonzalez P, Martin M, Garcia-Castro M, Iglesias-Cubero G, Cortina A. 5-hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction. Clinical Science. 2003;104:241-245.
11. Muldoon MF, Nazzaro P, Sutton-Tyrrell K, Manuck SB. White-coat hypertension and carotid artery atherosclerosis: a matching study. Arch Intern Med. 2000;160:1507-1512.
12. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc. 2001;285:2486-2497.
13. Matthews DR, Hosker JP, Rudenski A. S, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
14. Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 1996;11:5-11.
15. Lotrich FE, Bies R, Muldoon MF, Manuck SB, Smith GS, Pollock BG. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psychopharmacology 2005;178:268-275.
16. Flory JD, Manuck SB, Muldoon MF. Retest reliability of prolactin response to dl-fenfluramine challenge in adults. Neuropsychopharmacology. 2002;26:269-272.
17. Flory JD, Manuck SB, Perel JM, Muldoon MF. A comparison of d, l-fenfluramine and citalopram challenges in healthy adults. Psychopharmacology (Berl). 2004;174:376-380.
18. Wendelhag I, Gustavsson T, Suurkula M, Berglund G, Wikstrand J. Ultrasound measurement of wall thickness in the carotid artery: fundamental principles and description of a computerized analysing system. Clin Physiol. 1991;11:565-577.
19. Freedman LS, Schatzkin A. Sample size for studying intermediate endpoints within intervention trails or observational studies. Am J Epidemiol. 1992;136:1148-1159.
20. Chambless LE, Folsom AR, Davis V, Sharrett R, Heiss G, Sorlie P, Szklo M, Howard G, Evans GW. Risk factors for progression of common carotid atherosclerosis: The Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol. 2002;155:38-47.
21. Coccaro EF, Kavoussi RJ, Oakes M, Cooper TB, Hauger R. 5-HT2a/2c, receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects. Psychopharmacology. 1996;126:24-30.
22. Goodall E, Cowen P, Franklin M, Silverstone T. Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology. 1993;112:466.
23. Manuck SB, Flory JD, Muldoon MF, Ferrell RE. Central nervous system serotonergic responsivity and aggressive disposition in men. Physiol Behavior. 2002;77:705-709.
24. Manuck SB, Flory JD, Ferrell RE, Muldoon MF. Socio-economic status covaries with central nervous system serotonergic responsivity as a function of allelic variation in the serotonin transporter gene-linked polymorphic region. Psychoneuroendocrinology. 2004;29:651-668.
25. McCaffery JM, Frasure-Smith N, Dube MP, Theroux P, Rouleau GA, Duan QL, Lesperance F. Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med. 2006;68:187-200.
26. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747-2757.
27. Hansson GK. Mechanisms of disease - inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
28. Capuron L, Ravaud A, Miller AH, Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immunity. 2004;18:205-213.
29. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia. 2000;43:373-376.
30. Rosmond R, Bouchard C, Bjorntorp P. Increased abdominal obesity in subjects with a mutation in the 5-HT2A receptor gene promoter. Ann NY Acad Sci. 2002;967:571-575.
31. Wolff B, Grabe HJ, Volzke H, Ludemann J, Schwahn C, Freyberger H, John U, Langes M, Cascorbi I, Felix SB. A functional serotonin transporter (SLC6A4) polymorphism modifies the association of smoking and diabetes with asymptomatic carotid atherosclerosis. Thromb Haemost. 2005;93:180-182.
32. Arinami T, Ohtsuki T, Yamakawa-Kobayashi K, Amemiya H, Fujiwara H, Kawata K, Ishiguro H, Hamaguchi H. A synergistic effect of serotonin transporter gene polymorphism and smoking in association with CHD. Thromb Haemost. 1999;81:853-856.
33. Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup A. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metab Clin Expe. 1995;44:1570-1576.
34. Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, VanGaal L. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obesity Res. 1996;4:391-396.
35. Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obesity. 1997;21:97-102.
36. Vanloon BJP, Radder JK, Frolich M, Krans HMJ, Zwinderman AH, Meinders AE. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals. Int J Obesity. 1992;16:79-85.
37. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894-1898.
38. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Krishnan KRR, Van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701-709.
39. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108:32-36.
40. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, Kaufmann PG, Shuster J, Mellman T, Blumenthal JA, Krishnan R, Jaffe AS. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psych. 2005;62:792-798.
41. Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psych. 1998;44:851-864.
42. Halford JCG, Harrold JA, Lawton CL, Blundell JE. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr Drug Targets. 2005;6:201-213.
43. Gami AS, Somers VK. Obstructive steep apnoea, metabolic syndrome, and cardiovascular outcomes. Eur Heart J. 2004;25:709-711.
44. Gangwisch JE, Heymsfield SB, Boden-Albala B, Buijs RM, Kreier F, Pickering TG, Rundle AG, Zammit GK, Malaspina D. Short sleep duration as a risk factor for hypertension: analyses of the first national health and nutrition examination survey. Hypertension. 2006;47:833-839.
45. Ramage AG. Central cardiovascular regulation and 5-hydroxytryptamine receptors. Brain Research Bulletin. 2001;56:425-439.
46. Stocker SD, Muldoon MF, Sved AF. Blunted fenfluramine-evoked prolactin secretion in hypertensive rats. Hypertension. 2003;42:719-724.
47. Luo S, Luo J, Cincotta AH. Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology. 1999;70:460-465.
48. Nonogaki K, Iguchi A. Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Life Sci. 1997;60:797-807.
49. Taylor AJ, Bobik A, Berndt MC, Kannelakis P, Jennings G. Serotonin blockade protects against early microvascular constriction following atherosclerotic plaque rupture. Eur J Pharmacol. 2004;486:85-89.
50. Suguro T, Watanabe T, Kanome T, Kodate S, Hirano T, Miyazaki A, Adachi M. Serotonin acts as an up-regulator of acyl-coenzyme A: cholesterol acyltransferase-1 in human monocyte-macrophages. Atherosclerosis. 2006;186:275-281.
51. Ban Y, Watanbe T, Miyazaki A, Nakano Y, Tobe T, Idei T, Iguchi T, Ban Y, Katagari T. Impact of increased plasma serotonin levels and carotid atherosclerosis on vascular dementia. Atherosclerosis. In press.
52. Hayashi T, Sumi D, Matsui-Hirai H, Fukatsu A, Rani PJA, Kano H, Tsunekawa T, Iguchi A. Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism. Atherosclerosis. 2003;168:23-31.
53. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther. 2000;68:435-442.
54. Serebruany VL, Suckow RF, Cooper TB, O'Connor CM, Malinin AI, Krishnan KRR, Van Zyl LT, Lekht V, Glassman AH. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am J Psych. 2005;162:1165-1170.
55. Manuck SB, Kaplan JR, Lotrich FE. Brain serotonin and aggressive disposition in humans and nonhuman primates. In: Nelson RJ, ed. Biology of Aggression. New York: Oxford University Press; 2005:65-113.